Medications for Stimulant Abuse: Agonist-Based Strategies and Preclinical Evaluation of the Mixed-Action D2 Partial Agonist Aripiprazole (Abilify®)

Experimental and Clinical Psychopharmacology

Volumn 16, Issue 6, 2008, Pages 475-483

  Bergman, Jack ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

aripiprazole; choice self administration procedures; D2 partial agonist; medications development; stimulant addiction

Indexed keywords

3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; BUPRENORPHINE; CAFFEINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; METHADONE; METHAMPHETAMINE; NALTREXONE; NICOTINE; OPIATE; PERGOLIDE; PROPYLNORAPOMORPHINE; TERGURIDE; VANOXERINE; VARENICLINE;

CATALEPSY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; HEROIN DEPENDENCE; HUMAN; IMMOBILIZATION; METHADONE TREATMENT; NONHUMAN; OPIATE ADDICTION; PRIMATE; REINFORCEMENT; REVIEW; SCRATCHING; SMOKING; SMOKING CESSATION; SQUIRREL MONKEY; SUBSTANCE ABUSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; HUMANS; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 57949101471     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0014398     Document Type: Review

References (52)

1. Ariens E.J. Intrinsic activity: Partial agonists and partial antagonists. Journal of Cardiovascular Pharmacology 5 (1983) S8-S15
2. Beresford T.P., Clapp L., Martin B., Wiberg J.L., Alfers J., and Beresford H.F. Aripiprazole in schizophrenia with cocaine dependence; a pilot study. Journal of Clinical Psychopharmacology 25 (2005) 363-366
3. Bergman J., France C.P., Holtzman S.G., Katz J.L., Koek W., and Stephens D.N. Agonist efficacy, drug dependence, and medications development: Preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology 153 (2000) 67-84
4. Bergman J., and Paronis C.A. Measuring the reinforcing strength of abused drugs. Molecular Interventions 6 (2006) 273-283
5. Brauer L.H., and de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biological Psychiatry 39 (1996) 26-32
6. Brauer L.H., and de Wit H. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacology Biochemistry and Behavior 56 (1997) 265-272
7. Brown E.S., Jeffres J., Liggin J.D., Garza M., and Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotics to aripiprazole. Journal of Clinical Psychiatry 66 (2005) 756-760
8. Dole V.P., and Nyswander M.E. Heroin addiction-A metabolic disease. Archives of Internal Medicine 120 (1967) 19-24
9. Feltenstein M.W., Altar C.A., and See R.E. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biological Psychiatry 61 (2007) 582-590
10. Gasior M., Paronis C.A., and Bergman J. Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys. Journal of Pharmacology and Experimental Therapeutics 308 (2004) 249-259
11. Giardina W.J., and Williams M. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: Preclinical pharmacology and clinical data. CNS Drug Reviews 7 (2001) 305-316
12. Goldstein A. Heroin addiction: Sequential treatment employing pharmacological supports. Archives of General Psychiatry 33 (1976) 353-358
13. Gorelick D.A., and Wilkins J.N. Bromocriptine treatment for cocaine addiction: Association with plasma prolactin levels. Drug and Alcohol Dependence 81 (2006) 189-195
14. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., and Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21 (2001) 522-526
15. Gunne L.M., Anggard E., and Jonsson L.E. Clinical trials with amphetamine-blocking drugs. Psychiatria, Neurologia, Neurochirurgia 75 (1972) 225-226
16. 1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 143 (1999) 102-110
17. Haney M., Foltin R.W., and Fischman M.W. Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology 137 (1998) 15-24
18. Haney, M., Hart, C. L., Reed, S. C., Vosburg, S. K., Foltin, & R. W. (2007). Aripiprazole increases cocaine self-administration in humans. Presented at International Study Group Investigating Drugs as Reinforcers, Québec City, Canada.
19. Haney M., and Spealman R.D. Controversies in translational research: Drug self-administration. Psychopharmacology 199 (2008) 403-419
20. 1 antagonist, on smoked cocaine self-administration in humans. Psychopharmacology 155 (2001) 330-337
21. Howell L.L., and Kimmel H.L. Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology 75 (2008) 196-217
22. Izzo E., Orsini C., Koob G.F., and Pulvirenti L. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacology Biochemistry and Behavior 68 (2001) 701-708
23. Kleber H.D. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues in Clinical Neuroscience 9 (2007) 455-470
24. Leshner A.I., and Koob G.F. Drugs of abuse and the brain. Proceedings of the Association of American Physicians 111 (1999) 99-108
25. Lile J.A., Stoops W.W., Vansickel A.R., Glaser P.E.A., Hays L.R., and Rush C.R. Aripiprazole attenuates the discriminative stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology 30 (2005) 2103-2114
26. Lobmaier P., Kornør H., Kunøe N., and Bjørndal A. Sustained-release naltrexone for opioid dependence [Electronic version]. Cochrane Database of Systematic Reviews 2 (2008) CD006140
27. Malcolm R., Herron J., Sutherland S.E., and Brady K.T. Adverse outcomes in a controlled trial of pergolide for cocaine dependence. Journal of Addictive Diseases 20 (2001) 81-92
28. 1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology 160 (2002) 362-370
29. 1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology 155 (2001) 338-347
30. Negus S.S., and Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70 (2003) 39-52
31. Negus S.S., and Mello N.K. Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology 167 (2003) 324-332
32. Newton T.F., Reid M.S., De La Garza R., Mahoney J.J., Abad A., Condos R., et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers [Electronic version]. International Journal of Neuropsychopharmacology (2008) DOI: 10.1017/S1461145708009097
33. Paronis C.A., Maciej Gasior M., and Bergman J. Effects of cocaine under concurrent fixed ratio schedules of food and IV drug availability: A novel choice procedure in monkeys. Psychopharmacology 163 (2002) 283-291
34. 2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology 166 (2003) 298-305
35. Platt D.M., Rowlett J.K., and Spealman R.D. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163 (2002) 265-282
36. Preston K.L., Sullivan J.T., Strain E.C., and Bigelow G.E. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. Journal of Pharmacology and Experimental Therapeutics 262 (1992) 279-291
37. Pulvirenti L., and Koob G.F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends in Pharmacological Sciences 15 (1994) 374-379
38. 1 receptor agonists in squirrel monkeys. European Journal of Pharmacology 260 (1994) 237-241
39. 2 agonists in squirrel monkeys. Psychopharmacology 116 (1994) 9-18
40. Rothman R.B., Blough B.E., and Baumann M.H. Dual Dopamine/Serotonin Releasers: Potential Treatment Agents for Stimulant Addiction. Experimental and Clinical Psychopharmacology 16 (2008) 458-474
41. Rothman R.B., and Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: Focus on GBR 12909. Molecular Neurobiology 11 (1995) 1-19
42. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.-X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
43. Sherer M.A., Kumor K.M., and Jaffe J.H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Research 27 (1989) 117-125
44. Soares B.G., Lima M.S., Reisser A.A., and Farrell M. Dopamine agonists for cocaine dependence [Electronic version]. Cochrane Database of Systematic Reviews 2 (2003) CD003352
45. Sørensen G., Sager T.N., Petersen J.H., Brennum L.T., Thøgersen P., Hee-Bengtsen C., et al. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology 199 (2008) 37-46
46. Stoops W.W., Lile J.A., Glaser P.E.A., and Rush C.R. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug and Alcohol Dependence 84 (2006) 206-209
47. Sung S., and Conry J.M. Role of buprenorphine in the management of heroin addiction. Annals of Pharmacotherapy 40 (2006) 501-505
48. Thomsen T., Fink-Jensen A., Woldbye D.P.D., Wörtwein G., Sager T.N., Holm R., et al. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats [Electronic version]. Psychopharmacology (2008) DOI 10.1007/s00213-008-1245-1
49. Tidey J.W., and Bergman J. Drug discrimination in methamphetamine-trained monkeys: Agonist and antagonist effects of dopaminergic drugs. Journal of Pharmacology and Experimental Therapeutics 285 (1998) 1163-1174
50. Tiihonen J., Kuoppasalmi K., Föhr J., Tuomola P., Kuikanmäki O., Vorma H., et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. American Journal of Psychiatry 164 (2007) 160-162
51. Wachtel S.R., Ortengren A., and de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug and Alcohol Dependence 68 (2002) 23-33
52. 2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32 (2007) 2238-2247